I found a site that has 1mg pills for a reasonable price:
Lots of discussion and links to related research papers on this topic from an earlier post in the Rapamycin for Hair and Skin thread:
Conclusion
Oral minoxidil 5 mg once daily effectively increased hair growth in our male patients with AGA and had a good safety profile in healthy subjects. However, oral minoxidil should be used carefully with men who have severe hypertension and increased risk for cardiovascular events.
Back in the dark room looking for the black cat.
Reengineering a Classic
As you read this, minoxidil (which can be used topically or taken in pill form) remains the gold standard solution for hair loss. Originally prescribed as a blood pressure medication, researchers still aren’t exactly sure how it works, though it’s currently FDA-approved to treat androgenetic alopecia and commonly used off-label to treat hair disorders such as alopecia areata and scarring alopecia.
Effective, yes—but not without its drawbacks. In addition to rare negative cardiac events, it also tends to take a long time to work, with initial results showing up at around the six-month mark. More substantial changes don’t appear until around twelve months or more, says Reid Waldman, MD, a board-certified dermatologist and chief executive officer and board member of Veradermics. This bug is ultimately part of the design: “The way in which oral minoxidil performs in the body is exactly how you would expect it to as a blood pressure medication—it spikes quickly in blood plasma and, within four hours, the majority of it is gone,” says Dr. Waldman. “Hair follicles, on the other hand, need consistent and durable exposure over time to experience an improvement.”
Veradermics believes it has the solution: VDPHL01, an extended-release oral minoxidil that allows for sustained absorption. According to three posters that Veradermics presented at the recent AAD meeting, VDPHL01, currently in phase 3 trials, demonstrated superior efficacy and faster onset than current oral minoxidil medications. One of the posters, Comparative Efficacy of an Investigational Oral Minoxidil Extended-Release Tablet (VDPHL01) Versus Existing Minoxidil Formulations in Androgenetic Alopecia: A Blinded Retrospective IGA Analysis , demonstrated visible improvement at two months versus six months for topical or oral minoxidil. “It’s clearly safe and it works better than the current oral minoxidil,” says Dr. Goldberg, whose practice, Schweiger Dermatology, has been involved in conducting these trials.
Despite the fact that neither treatment is currently available—it may be a year or more before they are—the technology has dermatologists excited. “Oral minoxidil is part of my practice every single day and while it’s generally well-tolerated for the vast majority of patients, I still see someone every few months who has to stop because of chest tightness, palpitations, or headaches,” says Robert Finney, MD, a board-certified dermatologist who specializes in hair loss and founder of Soho Skin & Hair Restoration. “The hope with Veradermics’ formulation is that by keeping blood concentrations lower and more stable—avoiding those early peaks—some of those patients may be able to tolerate it where they couldn’t before. That alone would be clinically meaningful.”
VDPHL01 (Extended-Release Oral Minoxidil)
VDPHL01 is an investigational non-hormonal drug candidate developed by Veradermics for the treatment of androgenetic alopecia (pattern hair loss).
Dosing
In its pivotal Phase 3 clinical trials (e.g., Study 304), VDPHL01 is being evaluated at a primary dose of 8.5 mg. Trial protocols are assessing the efficacy of this dose administered under both once-daily (QD) and twice-daily (BID) regimens. Previous Phase 2/3 dose-finding trials also evaluated 5 mg and 10 mg strengths to establish the optimal therapeutic window.
Duration of Absorption
Traditional immediate-release oral minoxidil is absorbed rapidly into the bloodstream, reaching peak plasma concentration (Cmax) within 1 to 2 hours and clearing systemically within 4 hours.
In contrast, VDPHL01 utilizes a proprietary extended-release gel matrix that dissolves gradually in the stomach. This creates a sustained duration of absorption that smoothly extends across the daily dosing interval. By slowing the absorption rate, VDPHL01 prevents sharp systemic spikes above the “cardiac activity threshold” (which can trigger adverse effects like tachycardia and edema).
This sustained absorption is mechanistically important: minoxidil is a prodrug that must be converted to its active form (minoxidil sulfate) by sulfotransferase enzymes (SULT1A1) located in the outer root sheath of the hair follicle. Because these local enzymes are capacity-limited and time-dependent, they process steady, long-lasting drug exposure much more effectively than brief, rapid spikes.
Half-Life
The intrinsic physiological elimination half-life of the minoxidil molecule itself remains short at 3 to 4 hours.
However, VDPHL01 operates on a principle of “flip-flop pharmacokinetics.” Because the extended-release tablet delivers the drug into the gastrointestinal tract much slower than the kidneys clear it from the blood, the prolonged absorption rate becomes the rate-limiting step for systemic clearance. As a result, while the true metabolic half-life of minoxidil is unchanged, the effective half-life of the VDPHL01 formulation is extended significantly. This allows plasma levels to remain consistently above the minimum threshold required to stimulate hair growth throughout the entire 12- to 24-hour dosing window.